Tenderwize
Retour à la recherche

Non-exclusive pharmaceutical discount agreement under Open-House model for Oralair(R) (ATC V01AA02)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Aug 31, 2028 · 741 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

20/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

20 / 100

Complexité

30 / 100

Facteurs de risque

The buyer reserves the right to terminate the Open-House process early if exclusive discount agreements are concluded...

No minimum purchase volumes; actual demand depends on patient numbers, prescription behavior, and pharmacy stocking. Re...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Aug 2028
  • Non-exclusive discount agreements for Oralair(R) (ATC V01AA02) under § 130a Abs. 8 SGB V
  • Supply of pharmaceutical product including parallel and re-imports
Afficher le résumé complet

This is a non-exclusive pharmaceutical discount agreement under an Open-House model for the drug Oralair(R) (ATC V01AA02), organized by AOK PLUS for Saxony and Thuringia. The agreement is not a formal public procurement but a voluntary transparency notice. Any qualified pharmaceutical entrepreneur can join by submitting participation documents via the DTVP portal. The first submission deadline is August 5, 2026, with periodic deadlines thereafter. The agreement ends on August 31, 2028. No estimated value, guaranteed volumes, or award criteria are provided. The process is open but subject to confidentiality and early termination if exclusive agreements are concluded.

Risques

The buyer reserves the right to terminate the Open-House process early if exclusive discount agreements are concluded...

No minimum purchase volumes; actual demand depends on patient numbers, prescription behavior, and pharmacy stocking. Re...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG

Eligibility

  • Must submit declaration of no exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen)

Administrative

  • Must submit Russia sanctions declaration (Eigenerklärung Russlandsanktionen)

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical discount agreement under Open-House model for Oralair(R) (ATC V01AA02)

This lot covers the conclusion of non-exclusive discount agreements for the pharmaceutical product Oralair(R) (ATC V01AA02), including parallel and re-imports. The contract is under an Open-House model, with rolling submission deadlines. The agreement ends on August 31, 2028. No minimum volume or exclusivity is guaranteed.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Aug 2026 - Aug 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Aug 31, 2028

Détails de la procédure

Date de publication
09 Jul 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
477144-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026

Aug 21

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9